Biocon's Liraglutide Injection Gains USFDA Approval, Targeting Obesity Market

Biocon Secures US FDA Approval for Liraglutide Injection to Tap Growing GLP-1 Market​

Biocon Receives US FDA Nod for Complex Liraglutide Formulation​

Biocon Ltd announced on Tuesday that it has received approval from the US Food and Drug Administration for its complex formulation, Liraglutide Injection, 18 mg per 3 mL, in single-patient-use prefilled pens.

The approval marks a significant regulatory milestone for the biotechnology firm as it expands its footprint in the United States with a drug-device combination product designed for chronic weight management.

Liraglutide is indicated as an adjunct to a reduced-calorie diet and increased physical activity for patients requiring long-term weight management support.

GLP-1 Therapies: A Fast-Growing Global Segment​

Glucagon-like peptide-1 receptor agonists are among the fastest-growing therapeutic classes worldwide. Growth in this segment is driven by the rising prevalence of obesity and metabolic disorders, strong clinical outcomes, and increasing physician adoption.

According to IQVIA MAT December 2025 data, the total addressable market opportunity for GLP-1 therapies in weight loss in the United States stood at 127 million dollars, underlining the commercial potential for approved products in this category.

The US market remains central to Biocon’s growth strategy in the GLP-1 segment.

Management Commentary on Strategic Milestone​

Siddharth Mittal, Chief Executive Officer and Managing Director of Biocon Ltd, described the approval as a defining milestone for the company.

He said the US approval validates the company’s scientific depth, vertically integrated development and manufacturing platform, and its capability to bring complex drug products to global markets.

Mittal added that GLP-1 therapies represent a significant growth driver for the company, with the US being an important market. He reiterated the company’s commitment to commercialising Liraglutide at the earliest to ensure patients in the United States have access to a high-quality and affordable treatment option.

What Is Glucagon-Like Peptide-1​

Glucagon-like peptide-1 medications help lower blood sugar levels and promote weight loss. These physiological hormones act through GLP-1 receptors released from gut enteroendocrine cells.

They control meal-related glycaemic excursions by augmenting insulin secretion and inhibiting glucagon release. GLP-1 also slows gastric emptying and reduces food intake, thereby maximising nutrient absorption while limiting weight gain.

What Is Liraglutide​

Liraglutide is a synthetic analog of the GLP-1 peptide and is administered as a once-daily injection.

It was approved for medical use in the European Union in 2009 and in the United States in 2010.

In 2014, Liraglutide received approval from the US Food and Drug Administration for adults who are obese or overweight with at least one weight-related condition. A year later, it was approved by the European Medicines Agency for similar indications.

In 2019, the US Food and Drug Administration approved Liraglutide for the treatment of children aged ten years or older with type 2 diabetes. It became the first non-insulin drug approved for type 2 diabetes in children since metformin was cleared in 2000.

Biocon Share Price Reaction​

Shares of Biocon Ltd ended at ₹390.35 on the BSE, up ₹2.55 or 0.66 percent for the day, reflecting investor response following the regulatory development.